美国Quanterix 
Quanterix公司是单分子检测领域的领先者，该公司宣布经过A轮第二回合的融资，使公司总募资额达到1500万美元。所募资金将用于启动试验平台并加快面向各种生物分析物的超灵敏化验技术的发展。Quanterix公司的单分子检测技术将会使临床诊断、药物研发和生命科学研究具有更高的灵敏度、精确度和更好的结果完全性。

Quanterix is a development stage company innovating ultra–sensitive detection systems for use in research and in–vitro diagnostics. Quanterix Single Molecule Array (SiMoA™) technology enables researchers and clinicians to gain completely new insights into disease by detecting previously hard to detect or undetectable biomarkers. For example, the unparalleled sensitivity of SiMoA allows the detection of very low virus concentrations at the earliest stages of infection without the need for amplification.

The digital nature of Quanterix’s SiMoA technology results in a 1,000–fold improvement in sensitivity compared with current state–of–the art technology. This technology enables life science researchers to validate novel, low abundance biomolecules from In addition, healthcare practitioners can use SiMoA for improved diagnosis, therapy selection and disease monitoring.

Poised to become the new industry standard, a fully automated cost–effective SiMoA instrument platform and proprietary reagents and consumables are being developed now. This breakthrough system will address the needs of the life science and diagnostics markets:

Detect biological markers and pathways considered difficult or impossible to measure with today’s technology, with the ability to customize SiMoA assays for research use only

Enable new assays based on clinically valuable biomarkers identifiable only through SiMoA–based platforms

Increase clinical performance of existing tests operating near the limits of current technology

Provide the highest sensitivity and best precision over a wide dynamic range with multiplex capability and rapid turnaround time

Provide these tremendous improvements in performance at a cost point that is consistent with clinical and research needs

Founded in 2007, Quanterix is the exclusive licensee of a broad intellectual property portfolio initially developed at Tufts University by Dr. David Walt, scientific founder of Quanterix and Illumina (NASDAQ: ILMN)